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Abstract
The Juvenile Arthritis Multidimensional Assessment Report (JAMAR) is a new parent/patient reported outcome measure that 
enables a thorough assessment of the disease status in children with juvenile idiopathic arthritis (JIA). We report the results 
of the cross-cultural adaptation and validation of the parent and patient versions of the JAMAR in the Argentinian Spanish 
language. The reading comprehension of the questionnaire was tested in 10 JIA parents and patients. Each participating 
centre was asked to collect demographic, clinical data and the JAMAR in 100 consecutive JIA patients or all consecutive 
patients seen in a 6-month period and to administer the JAMAR to 100 healthy children and their parents. The statistical 
validation phase explored descriptive statistics and the psychometric issues of the JAMAR: the three Likert assumptions, 
floor/ceiling effects, internal consistency, Cronbach’s alpha, interscale correlations, test–retest reliability, and construct 
validity (convergent and discriminant validity). A total of 373 JIA patients (23.1% systemic, 30.8% oligoarticular, 28.1% RF 
negative polyarthritis, 18% other categories) and 100 healthy children were enrolled in five centres. The JAMAR components 
discriminated well healthy subjects from JIA patients. Notably, there was no significant difference between healthy subjects 
and their affected peers in the school-related item. All JAMAR components revealed good psychometric performances. In 
conclusion, the Argentinian Spanish version of the JAMAR is a valid tool for the assessment of children with JIA and is 
suitable for use both in routine clinical practice and clinical research.
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Introduction
The aim of the present study is to cross-culturally adapt and 
validate the Argentinian Spanish parent and patient ver-
sions of the Juvenile Arthritis Multidimensional Assessment 
Report (JAMAR) [1] in patients with juvenile idiopathic 
arthritis (JIA). The JAMAR assesses the most relevant 
parent/patient reported outcomes in JIA, including overall 
well-being, functional status, health-related quality of life 
(HRQoL), pain, morning stiffness, disease activity/status/
course, articular and extra-articular involvement, drug-
related side effects/compliance and satisfaction with illness 
outcome.
This project was part of a larger multinational study con-
ducted by the Paediatric Rheumatology International Trials 
Organisation (PRINTO) [2] aimed to evaluate the Epide-
miology, Outcome and Treatment of Childhood Arthritis 
(EPOCA) in different geographic areas [3].
We report herein the results of the cross-cultural adapta-
tion and validation of the parent and patient versions of the 
JAMAR in the Argentinian Spanish language.
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Materials and methods
The methodology employed has been described in detail in 
the introductory paper of the supplement [4]. In brief, it was 
a cross-sectional study of JIA children, classified according 
to the ILAR criteria [5, 6] and enrolled from June 2012 to 
December 2014. Children were recruited after Ethics Com-
mittee approval and consent from at least one parent.
The JAMAR
The JAMAR [1] includes the following 15 sections:
 1. Assessment of physical function (PF) using 15 items 
in which the ability of the child to perform each task 
is scored as follows: 0 = without difficulty, 1 = with 
some difficulty, 2 = with much difficulty, 3 = unable to 
do and not applicable if it was not possible to answer 
the question or the patient was unable to perform the 
task due to their young age or to reasons other than 
JIA. The total PF score ranges from 0 to 45 and has 
three components: PF-lower limbs (PF-LL), PF-hand 
and wrist (PF-HW) and PF-upper segment (PF-US) 
each scoring from 0 to 15 [7]. Higher scores indicating 
higher degree of disability [8–10];
 2. rating of the intensity of the patient’s pain on a 
21-numbered circle visual analogue scale (VAS) [11];
 3. assessment of the presence of joint pain or swelling 
(present/absent for each joint);
 4. assessment of morning stiffness (present/absent);
 5. assessment of extra-articular symptoms (fever and 
rash) (present/absent);
 6. rating of the level of disease activity on a 21-circle 
VAS;
 7. rating of disease status at the time of the visit (categori-
cal scale);
 8. rating of disease course from previous visit (categori-
cal scale);
 9. checklist of the medications the patient is taking (list 
of choices);
 10. checklist of side effects of medications;
 11. report of difficulties with medication administration 
(list of items);
 12. report of school/university/work problems caused by 
the disease (list of items);
 13. assessment of HRQoL, through the Physical Health 
(PhH), and Psychosocial Health (PsH) subscales (five 
items each) and a total score. The four-point Likert 
response, referring to the prior month, are ‘never’ 
(score = 0), ‘sometimes’ (score = 1), ‘most of the time’ 
(score = 2) and ‘all the time’ (score = 3). A ‘not assess-
able’ column was included in the parent version of the 
questionnaire to designate questions that cannot be 
answered because of developmental immaturity. The 
total HRQoL score ranges from 0 to 30, with higher 
scores indicating worse HRQoL. A separate score for 
PhH and PsH (range 0–15) can be calculated [12–14];
 14. rating of the patient’s overall well-being on a 21-num-
bered circle VAS;
 15. a question about satisfaction with the outcome of the 
illness (yes/no) [15].
The JAMAR is available in three versions, one for parent 
proxy-report (child’s age 2–18), one for child self-report, 
with the suggested age range of 7–18 years, and one for 
adults.
Cross cultural adaptation and validation
The process of cross-cultural adaptation was conducted 
according to international guidelines with 2–3 forward and 
backward translations. In those countries for which the trans-
lation of JAMAR had been already cross-cultural adapted 
in a similar language (i.e. Spanish in South American coun-
tries), only the probe technique was performed. Reading 
comprehension and understanding of the translated ques-
tionnaires were tested in a probe sample of 10 JIA parents 
and 10 patients.
Each participating centre was asked to collect demo-
graphic, clinical data and the JAMAR in 100 consecutive 
JIA patients or all consecutive patients seen in a 6-month 
period and to administer the JAMAR to 100 healthy children 
and their parents.
The statistical validation phase explored the descriptive 
statistics and the psychometric issues [16]. In particular, we 
evaluated the following validity components: the first Lik-
ert assumption [mean and standard deviation (SD) equiva-
lence]; the second Likert assumption or equal items–scale 
correlations (Pearson r: all items within a scale should con-
tribute equally to the total score); third Likert assumption 
(item internal consistency or linearity for which each item 
of a scale should be linearly related to the total score that is 
90% of the items should have Pearson r ≥ 0.4); floor/ceiling 
effects (frequency of items at lower and higher extremes of 
the scales, respectively); internal consistency, measured by 
the Cronbach’s alpha, interscale correlation (the correlation 
between two scales should be lower than their reliability 
coefficients, as measured by Cronbach’s alpha); test–retest 
reliability or intraclass correlation coefficient (reproducibil-
ity of the JAMAR repeated after 1 or 2 weeks); and construct 
validity in its two components: the convergent or external 
validity which examines the correlation of the JAMAR sub-
scales with the 6 JIA core set variables, with the addition 
of the parent assessment of disease activity and pain by the 
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Spearman’s correlation coefficients (r) [17] and the discri-
minant validity, which assesses whether the JAMAR dis-
criminates between the different JIA categories and healthy 
children [18].
Quantitative data were reported as medians with 1st and 
3rd quartiles and categorical data as absolute frequencies 
and percentages.
The complete Argentinian Spanish parent and patient ver-
sions of the JAMAR are available upon request to PRINTO.
Results
Cross cultural adaptation
The Argentinian Spanish JAMAR was fully cross-cultur-
ally adapted from the standard English version with two 
forward and two backward translations with a concordance 
for 118/123 (95.9%) translations lines for the parent ver-
sion and 116/120 (96.7%) lines for the child version. Of the 
123 lines in the parent version of the JAMAR, 115 (93.5%) 
were understood by at least 80% of the 10 parents tested 
(median = 100%; range 50–100%). In the patient version of 
the JAMAR, 119/120 (99.2%) lines were understood by at 
least 80% of the children (median = 100%; range 60–100%). 
Lines 11, 64, 65, 83, 84, 87, 88, 96 of the parent JAMAR 
and line 62 of the child JAMAR were modified according to 
parents’ and patients’ suggestions.
Demographic and clinical characteristics 
of the subjects
A total of 373 JIA patients and 100 healthy children (total 
of 473 subjects), were enrolled at five paediatric rheumatol-
ogy centres.
In the 373 JIA subjects, the JIA categories were 23.1% 
with systemic arthritis, 30.8% with oligoarthritis, 28.1% 
with RF negative polyarthritis, 9.9% with RF positive pol-
yarthritis, 1.3% with psoriatic arthritis, 6.2% with enthesi-
tis related arthritis and 0.5% with undifferentiated arthritis 
(Table 1).
A total of 472/473 (99.8%) subjects had the parent ver-
sion of the JAMAR completed by a parent (373 from parents 
of JIA patients and 99 from parents of healthy children). 
The JAMAR was completed by 434/472 (91.9%) mothers 
and 38/472 (8.1%) fathers. The child version of the JAMAR 
was completed by 395/473 (83.5%) children age 6.2 or older. 
Also patients younger than 7 years old, capable to assess 
their personal condition and able to read and write, were 
asked to fill in the patient version of the questionnaire.
Discriminant validity
The JAMAR results are presented in Table 1, including 
the scores [median (1st–3rd quartile)] obtained for the PF, 
the PhH, the PsH subscales and total score of the HRQoL 
scales. The JAMAR components discriminated well between 
healthy subjects and JIA patients.
In summary, the JAMAR revealed that JIA patients had 
a greater level of disability and pain, as well as a lower 
HRQoL than their healthy peers. However, there was no 
significant difference between healthy subjects and their 
affected peers in the school-related item.
Psychometric issues
The main psychometric properties of both parent and child 
versions of the JAMAR are reported in Table 2. The fol-
lowing results section refers mainly to the parent’s version 
findings, unless otherwise specified.
Descriptive statistics (first Likert assumption)
There were no missing results for all JAMAR items, since 
data were collected through a web-based system that did not 
allow to skip answers or input null values. The response pat-
tern for both PF and HRQoL was positively skewed toward 
normal functional ability and normal HRQoL. All response 
choices were used for the different HRQoL items, whereas a 
reduced number of response choices were used for PF items 
5.
The mean and SD of the items within a scale were 
roughly equivalent for the PF and for the HRQoL items 
(data not shown). The median number of items marked as 
not applicable was 1% (0–1%) for the PF and 3.5% (2–6%) 
for the HRQoL.
Floor and ceiling effect
The median floor effect was 85% (83.6–90.9%) for the PF 
items, 74% (64.3–77.7%) for the HRQoL PhH items, and 
74.3% (66.8–75.1%) for the HRQoL PsH items. The median 
ceiling effect was 0.5% (0.5–1.6%) for the PF items, 1.3% 
(1.1–2.9%) for the HRQoL PhH items, and 1.3% (1.1–2.6%) 
for the HRQoL PsH items. The median floor effect was 
50.1% for the pain VAS, 47.4% for the disease activity VAS 
and 50.9% for the well-being VAS. The median ceiling effect 
was 0.5% for the pain VAS, 1.3% for the disease activity 
VAS and 0.8% for the well-being VAS.
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Equal items–scale correlations (second Likert 
assumption)
Pearson items–scale correlations corrected for overlap were 
roughly equivalent for items within a scale for 93% of the 
PF items, with the exception of PF item 15, and for 100% of 
the HRQoL items.
Items internal consistency (third Likert assumption)
Pearson items–scale correlations were ≥ 0.4 for 100% of 
items of the PF and 100% of items of the HRQoL.
Table 2  Main psychometric characteristics between the parent and child version of the JAMAR
JAMAR Juvenile Arthritis Multidimensional Assessment Report, JIA juvenile idiophatic arthritis, VAS visual analogue scale, PF physical func-
tion, HRQoL health-related quality of life, PhH physical Health, PsH psychosocial health, PF-LL PF-lower limbs, PF-HW PF-hand and wrist, 
PF-US PF-upper segment
Parent N = 373/472 Child N = 321/395
Missing values (1st–3rd quartiles) No missing values No missing values
Response pattern PF and HRQoL positively skewed PF and HRQoL positively skewed
Floor effect, median
 PF 85.0% 87.2%
 HRQoL PhH 74.0% 72.9%
 HRQoL PsH 74.3% 73.2%
 Pain VAS 50.1% 49.2%
 Disease activity VAS 47.4% 51.1%
 Well-being VAS 50.9% 54.5%
Ceiling effect, median
 PF 0.5% 0.3%
 HRQoL PhH 1.3% 1.9%
 HRQoL PsH 1.3% 2.2%
 Pain VAS 0.5% 0.9%
 Disease activity VAS 1.3% 0.9%
 Well-being VAS 0.8% 0.9%
Items with equivalent item–scale correlation 93% for PF, 100% for HRQoL 87% for PF, 90% for HRQoL
Items with items–scale correlation ≥ 0.4 100% for PF, 100% for HRQoL 100% for PF, 100% for HRQoL
Cronbach’s alpha
 PF-LL 0.92 0.87
 PF-HW 0.91 0.85
 PF-US 0.88 0.85
 HRQoL PhH 0.83 0.82
 HRQoL PsH 0.79 0.82
Items with item–scale correlation lower than the Cronbach’s alpha 100% for PF, 100% for HRQoL 100% for PF, 100% for HRQoL
Test–retest intraclass correlation
 PF total score 0.97 0.98
 HRQoL PhH 0.88 0.97
 HRQoL PsH 0.79 0.90
Spearman correlation with JIA core-set variables, median
 PF 0.6 0.6
 HRQoL PhH 0.6 0.6
 HRQoL PsH 0.3 0.3
 Pain VAS 0.5 0.5
 Disease activity VAS 0.5 0.5
 Well-being VAS 0.5 0.5
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Cronbach’s alpha internal consistency
Cronbach’s alpha was 0.92 for PF-LL, 0.91 for PF-HW, 0.88 
for PF-US. Cronbach’s alpha was 0.83 for HRQoL PhH and 
0.79 for HRQoL PsH.
Interscale correlation
The Pearson correlation of each item of the PF and the 
HRQoL with all items included in the remaining scales of 
the questionnaires was lower than the Cronbach’s alpha.
Test–retest reliability
Reliability was assessed in 47 JIA patients, by re-adminis-
tering both versions (parent and child) of the JAMAR after a 
median of 3 days (0–7 days). The intraclass correlation coef-
ficients (ICC) for the PF total score showed an almost perfect 
reproducibility (ICC = 0.97). The ICC for the HRQoL PhH 
showed an almost perfect reproducibility (ICC = 0.88) while 
the ICC for the HRQoL PsH showed a substantial reproduc-
ibility (ICC = 0.79).
Convergent validity
The Spearman correlation of the PF total score with the 
JIA core set of outcome variables ranged from 0.5 to 0.6 
(median = 0.6). The PF total score best correlation was 
observed with the parent assessment of pain (r = 0.6, 
p < 0.001). For the HRQoL, the median correlation of the 
PhH with the JIA core set of outcome variables ranged from 
0.4 to 0.7 (median = 0.6), whereas for the PsH ranged from 
0.2 to 0.4 (median = 0.3). The PhH showed the best correla-
tion with the parent’s assessment of pain (r = 0.7, p < 0.001) 
and the PsH with the parent global assessment of well-being 
(r = 0.5, p < 0.001). The median correlations between the 
pain VAS, the well-being VAS, and the disease activity VAS 
and the physician-centered and laboratory measures were 0.5 
(0.3–0.6), 0.5 (0.4–0.5), 0.5 (0.4–0.6), respectively.
Discussion
In this study, the Argentinian Spanish version of the JAMAR 
was cross-culturally adapted from the original standard Eng-
lish version with two forward and two backward transla-
tions. According to the results of the validation analysis, 
the Argentinian Spanish parent and patient versions of the 
JAMAR possess satisfactory psychometric properties. Nota-
bly, there was no significant difference between the healthy 
subjects and their affected peers in the school-related prob-
lems variable. This finding indicates that children with JIA 
adapt well to the consequences of JIA, and have school 
performances comparable to those of their healthy peers. 
The PF total score proved to discriminate between the differ-
ent JIA subtypes with children with undifferentiated arthritis 
having a higher degree of disability.
Psychometric performances were good for all domains of 
the JAMAR and the overall internal consistency was good 
for all the domains.
In the external validity evaluation, the Spearman’s cor-
relations of the PF and HRQoL scores with JIA core set 
parameters ranged from moderate to strong.
The results obtained for the parent version of the JAMAR 
are very similar to those obtained for the child version, 
which suggests that children are equally reliable proxy 
reporters of their disease and health status as their parents.
The JAMAR is aimed to evaluate the side effects of medi-
cations and school attendance, which are other dimensions 
of daily life that were not previously considered by other 
HRQoL tools. This may provide useful information for inter-
vention and follow-up in health care.
In conclusion, the Argentinian Spanish version of the 
JAMAR was found to have satisfactory psychometric prop-
erties and it is, thus, a reliable and valid tool for the multidi-
mensional assessment of children with JIA.
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